Chiron: Partnering its dominance

Developing therapeutics for hepatitis C virus is so hard that Chiron Corp. has not been bashful about licensing rights giving just about all comers a crack at it. Last week, Merck and Co. Inc. became the seventh pharma company to which CHIR has licensed therapeutic HCV rights.

According to Bill Green, president of Chiron Blood

Read the full 550 word article

How to gain access

Continue reading with a
two-week free trial.